28 March
2024
Versarien
Plc
("Versarien", the "Company" or the "Group")
Audited Results for year
ended 30 September 2023
Versarien Plc (AIM: VRS), the advanced engineering materials
group, announces its audited results for the 12 months ended 30 September
2023. The comparative figures are for the 18 month period ended 30
September 2022.
The
Annual Report including the Notice of Annual General Meeting
("AGM") is now available on the Company's website at
www.versarien.com
and will be posted to shareholders on 30 March
2024. The AGM is being held on 30 April 2024 at 10.30 am
in the offices of FieldFisher LLP at
Riverbank House, 2 Swan Lane, London, EC4R 3TT.
Financial Highlights
•
|
Group revenues from continuing
operations of £5.45 million (2022: £11.11 million)*
|
•
|
Graphene revenues of £0.24 million
(2022: £2.15 million)
|
•
|
Adjusted LBITDA** for continuing
operations of £3.01 million (2022: £2.40 million)
|
•
|
H2 LBITDA** losses halved to £1.00
million from £2.01 million in H1
|
•
|
Asset impairments of £8.58 million
treated as an exceptional cost (2022: £1.33 million)
|
•
|
Reported loss before tax from
continuing operations of £14.27 million (2022: £8.32
million)
|
•
|
Reported loss for the period of
£14.18 million (2022: £8.41 million)
|
•
|
Cash of £0.60 million at 30
September 2023 (30 September 2022: £1.35 million)
|
•
|
£3.35 million gross raised via
equity placings during the period
|
•
|
£1.47 million gross raised via
equity placings post period end
|
* Excludes discontinued revenues of £nil
million (2022: £0.5 million)
** Adjusted LBITDA (Loss Before Interest, Tax, Depreciation
and Amortisation and excludes Exceptional items, Share-based
payment charges and losses)
Partnerships/Commercial Highlights
Construction
•
|
Key demonstration for the use of
CementeneTM in precast concretes following trials with
Banagher Precast Concrete Limited (Ireland)
|
•
|
Delivered the first 3D concrete
printed headwall to Costain and National Highways as part of the
A30 Chiverton to Carland Cross upgrade in Cornwall
|
•
|
Continued to be active as part of
advisory board of National Highways' Roads Research Alliance (RRA)
alongside more than 20 construction companies through involvement
in the Digital Roads of the Future Partnership
|
Leisure
•
|
Umbro have launched Spring/Summer
and Autumn/Winter 2023 Pro Training Elite collections integrated
with Graphene-WearTM
|
•
|
Signed a sales agreement with
GoToGym covering Colombia, Brazil and United States of America.
GoToGym Brazil have launched active-wear incorporating Versarien's
Graphene-WearTM technology
|
•
|
Continuing to
supply graphene enhanced elastomers to US-based Flux Footwear LLC,
an adaptive footwear company, with royalties in place for the use
of Versarien's Graphene-WearTM trademark
|
Technology Licencing
•
|
Versarien continues to licence 14
patents to GrapheneLab (Korea) for the manufacture of chemical
vapour deposition (CVD) graphene
|
Commercial R&D and Grant Funding
Highlights
•
|
Commercial R&D contracts were
signed with CBMM (Brazil), IRPC Public Company (Thailand) and a UK
aviation company
|
•
|
Successful on-time delivery of
Graphene Flagship Spearhead project led by Airbus Helicopters (GICE
project)
|
•
|
Gnanomat was awarded a grant from
ICEX Trade and Investment for €415,000 to enable the company to
commercialise and launch a new line of conductive inks
|
•
|
Commenced a 4-year long iCARE
(Integrated Assessment and Advanced Characterisation of
Neuro-Nanotoxicity) project (Horizon Europe), studying graphene in
different use cases including graphene enhanced concretes and
elastomers
|
Operational/Manufacturing Highlights
•
|
As part of cost cutting exercises,
the R&D team has been slimmed down significantly during 2023,
to concentrate on its strategic objectives
|
•
|
The Company has now ceased USA and
China sales operations in order to focus on its European operations
whilst maintaining its partnerships in South Korea
|
Post Period Highlights
•
|
Completed an agreement with MCK
Tech (Korea) for the exclusive licence of five CVD
patents.
|
•
|
Completed a know-how and
manufacturing licence agreement with Montana Quimica LTDA, a
Brazilian multinational focussed on the production of paints and
wood finishing products
|
•
|
Versarien Plc sold its South Korean
plant and equipment to MCK Tech (Korea) for £604,000
|
Dr Steve Hodge, CEO of Versarien,
commented:
"The period was a challenging one
for Versarien, but I believe the restructuring and other actions we
have undertaken have resulted in a more efficient business, which
maintains the skilled people and technology to enable commercial
success. It is encouraging to report that our pipeline of potential
income opportunities is growing , albeit development opportunities
are still the largest part, but we are beginning to see signs of
more commercial interest, including licensing. This, together with
our reduced cost base, gives us an increasing level of confidence
as we seek to ensure a bright future for Versarien."
This announcement contains inside information for the
purposes of Article 7 of the UK version of Regulation (EU) No
596/2014 which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018, as amended.
For further information please contact:
Versarien Plc
|
|
Dr Stephen Hodge - Chief Executive
Officer
|
c/o IFC
|
Chris Leigh - Chief Financial
Officer
|
|
|
|
SP Angel Corporate Finance (Nominated Adviser and Broker)
|
|
Matthew Johnson
Adam Cowl
|
+44 (0) 20 3470 0470
|
IFC Advisory Limited (Financial PR & Investor Relations)
|
|
Tim Metcalfe
Zach Cohen
|
+44 (0) 20 3934 6630
|
Notes to Editors:
The strategy of Versarien plc
(AIM:VRS) is to be a development led advanced materials company
focussed on specific sectors that will lead to a light
manufacturing and licensing model. For
further information please see: http://www.versarien.com
NON-EXECUTIVE CHAIR'S STATEMENT
The events of the last 12 months
have, to say the least, been extremely challenging for all
Versarien stakeholders as we streamlined the business in order to
navigate the current market traction difficulties and implement a
strategy that will provide a pathway to financial
viability.
Just prior to the AGM last year we
employed the expertise of turnaround specialist David Stone and he
has continued to work with us since then. Whilst shareholders will
rightly question whether any turnaround has been achieved, the
Board is confident that the Company's IP and technology is
commercially attractive. This is reflected in the increasing number
of opportunities the Company is seeing and the goal of
profitability is looking ever more achievable.
Our current projections are
suggesting that this will be in the second half of next year. In
the meantime, we will still need funds to bridge us to the point
that we are cash generative and we have been doing all we can to
market the two mature businesses whilst completing the sale of our
South Korean based plant and equipment.
We have closed down operations in
the US and China, reduced employee numbers in the remaining
operations and cut costs where possible and this is reflected in
the reduced operating losses in the second half of the year.
Nonetheless we have had no alternative but to continue to raise
equity funds from the stock market.
Notwithstanding these challenges,
I wish to reassure shareholders that we continue to do all we can
to progress the Company and are encouraged by the opportunities our
newly appointed CEO has provided through determination and hard
work. These are described in the CEO report.
I would like to thank all our
staff for their continued endeavours and very much look forward to
reporting further progress.
Diane Savory OBE
Non-executive Chair
CHIEF EXECUTIVE OFFICER'S REVIEW
The last 12 months have continued
to be turbulent with difficult but necessary cost-cutting measures
being implemented. Following this restructuring we have maintained
a highly skilled and loyal workforce with increased efficiency.
Whilst the Company still faces a number of macro-economic
challenges, we are confident that there are strong commercial and
R&D pipelines, including technology licensing opportunities
that give us confidence that we can improve the Company's position
and deliver a bright future.
We have a clear strategy
to:
•
|
focus on commercial opportunities
in the areas of construction and leisure
|
•
|
licence Versarien's technology,
brands and manufacturing know-how and become a manufacturing-light
operation
|
•
|
divest non-core activities to
reduce the requirement for funding from external sources
|
•
|
maintain and strengthen the Group's
scientific teams supported by grant funding applications
|
TECHNOLOGY BUSINESSES
UK operations
Following the G-SCALE project, we
switched focus to readying our manufacturing and quality control
processes for commercialisation. The last 12 months have continued
to be turbulent with difficult but necessary cost-cutting measures
being implemented. Following this restructuring we have maintained
a highly skilled and loyal workforce with increased
efficiency.
We have moved 2DT to a Tier 2
membership at the Graphene Engineering Innovation Centre (GEIC).
This has meant downsizing laboratory space and relocating some
equipment to Longhope. This has enabled our production staff to
upskill; we have set up coating stations for both
Graphene-WearTM formulation screen printing for customer
trials and set up graphene heater mat production with associated
heater mat assembly and electrothermal testing and
imaging.
Construction
This year we have worked with
several partners to continue to prove the effectiveness of graphene
as a powder and as an admixture (CementeneTM). In May
2023 we announced a key demonstration for the use of
CementeneTM in precast concretes following trials with
Banagher Precast Concrete Limited (Ireland) that showed we could
maintain compression strength whilst removing ~20% of the cement in
their standard mix. In line with our global ambitions, the
CementeneTM trademark is now granted in USA and South
Korea, in addition to the UK and EU registrations already in
place.
Versarien has supervised
researchers as part of the Digital Roads of the Future project led
by National Highways and Costain, housed at the University of
Cambridge and is proud to be part of the Advisory Board of the
Roads Research Alliance alongside the 20+ other founder
members.
In 2023, we continued to deliver
on a number of 3DCP projects. We delivered the first 3D concrete
printed headwall to Costain and National Highways as part of the
A30 Chiverton to Carland Cross upgrade in Cornwall. We are
incredibly proud to have built and delivered this first-of-a kind
UK highways structure that has certainly showcased our 3D print
team's capabilities while building project partners' confidence in
adopting innovative methods of construction.
Post period end, in October 2023,
Versarien won a public tender contract with the Office for Product
Safety and Standards (OPSS), part of the UK government's Department
for Business and Trade (DBT) to compile a comprehensive report
involving stakeholder reviews to support the UK's regulation of
3DCP within the existing Construction Products Regulation (CPR). We
have appointed a Head of 3D Construction Printing to continue to be
at the forefront of cutting-edge 3D Construction Printing
developments. We welcome the first international standard (ISO/ASTM
52939 Additive manufacturing for construction - Qualification
principles - Structural and infrastructure elements), published in
December 2023 that will enable us to implement more robust
practices when designing, manufacturing and delivering 3DCP
products.
Textiles and footwear
Versarien continues to progress
its relationships with a number of clothing brands. During 2023,
Umbro launched Spring/ Summer and Autumn/Winter 2023 Pro Training
Elite collections integrated with Graphene-WearTM. Post
period, in January 2024, we signed a sales agreement with GoToGym
covering Colombia, Brazil and United States of America. GoToGym
Brazil has launched active-wear incorporating Versarien's
Graphene-WearTM technology.
In footwear, we continue to supply
graphene enhanced elastomers to US-based Flux Footwear LLC, an
adaptive footwear company, with royalties in place for the use of
Versarien's Graphene-WearTM trademark.
Following successful product
launches we continue to take enquiries from global sportswear
brands for Graphene-WearTM enhanced products.
Grant Funding
In January 2023 we commenced a
4-year long iCARE (Integrated Assessment and Advanced
Characterisation of Neuro-Nanotoxicity) project (Horizon Europe)
studying graphene in different use cases including graphene
enhanced concretes and elastomers. The outputs of this project will
be critical in supporting the use of graphene in a wide array of
applications and give confidence to supply chain partners and
consumers.
In September 2023 we successfully
completed the Graphene Flagship SpearHead project GICE led by
Airbus. Principal aircraft de-icing/anti-icing components utilising
Versarien graphene heater mats were showcased to the EC reviewers
in Gothenburg in December 2023. These included NACA airfoils,
air-inlet scoop and helicopter rotor blade demonstrators. We
continue to seek grant funding to continue these developments and
in areas that align with our commercial focus areas.
OVERSEAS OPERATIONS
As part of cost cutting exercises
the Company has now ceased USA and China sales operations, in order
to focus on our Spanish and South Korean operations. We will
continue to operate from Spain and South Korea, but with a reduced
cost base.
Spain
Gnanomat has continued to test its
products in a wide range of markets, particularly in energy storage
with supercapacitors (pseudocapacitors), fuel cells and zinc/air
batteries as well as allied applications such as sensing and low
observability in military applications.
Due to challenging market
conditions, a decision was made to impair the carrying value of
goodwill and cost of investment in Gnanomat.
The Company is continuing to work
on the INNPRESSME grant project aiming to create an Open Innovation
Test Bed in the area of nanotechnology and advanced materials. The
funds have been used to optimise the pilot plant and gain access to
business opportunities.
Gnanomat has won two significant
commercial R&D contracts with CBMM (Brazil) and IRPC Public
Company (Thailand) and continues to apply for grants to support its
progress to commercial revenues.
South Korea
During the period, we saw CVD
graphene being used by customers for sensor development,
electrothermal heaters and optoelectronic devices.
Post period end, in March 2024 the
CVD plant and equipment was sold to MCK Tech Co. (Korea) for
£604,000 with an exclusive licence agreement for the use of five
patents.
Our objective is to continue to
develop a number of CVD graphene-based products with Korean
academic and commercial partners through commercially funded and
Korean national projects.
TECHNOLOGY LICENCING
Finding strategic partners who can
support our commercial progress will be essential as we transition
to a manufacturing-light operation in the UK, in line with the
Company's strategy to monetise intellectual property through
licensing.
In addition to 14 patents we
already licence to GrapheneLab Co Ltd, post period end, in March
2024, we granted an exclusive licence to MCK Tech, for an initial
period of five years, to use 5 CVD graphene production patents. MCK
Tech is a well-respected company that has developed graphene-based
sensors for healthcare. We look forward to maintaining access to
CVD graphene materials and supporting MCK Tech through
collaborative efforts.
We have also entered into a
manufacturing licence agreement and a know-how licence and
technical assistance agreement with Montana Química LTDA, a
Brazilian headquartered multinational business focused on the
production and sale of paints, wood preservatives and other wood
finishing products including stains and varnishes. We are very
pleased to be partnering with Montana Química, a leading business
in its markets in South America, and look forward to collaborating
closely with them as they bring products enhanced by Versarien's
technology to the market.
MATURE BUSINESSES
We continue to market both Total
Carbide Limited and AAC Cyroma Limited as they are not core to our
graphene activities. I am grateful to all staff at both businesses
for their continued support whilst this process is
underway.
CURRENT TRADING AND OUTLOOK
Our pipeline of opportunities
continues to strengthen which gives us increased confidence as we
seek to achieve profitability from our reduced cost base. We are
seeing more opportunities for our CementeneTM product in
particular from which we hope to secure ongoing revenue. We look
forward to reporting further progress in due course.
Dr Stephen Hodge
Chief Executive Officer
CHIEF FINANCIAL OFFICER'S REVIEW
These results are for a period of
12 months with the comparatives reflecting an 18-month
period. The aluminium business based at
Cheltenham closed last year and consequently these results are
split between continuing and
discontinued operations and the
segmental analysis between the technology and mature
businesses.
Group results
Revenues from continuing
operations were £5.45 million (2022: £11.11 million). Revenue from
graphene was £0.24 million (2022: £2.15 million). The loss from
operations was £13.72 million (2022: £7.69 million). The
comparative figure included a £1.19 million charge in respect of
the valuation of the Lanstead Sharing Agreements.
The adjusted LBITDA for continuing
operations was £3.01 million for 12 months compared to £2.40
million for the prior 18 months and is shown in the table below.
Adjusted LBITDA (which is not a GAAP measure and is not intended as
a substitute for GAAP measures and may not be the same as that used
by other companies) is a measure used by management to reflect the
core operating performance of the underlying businesses rather than
the effects of non-core financial and non-cash expenses. The
adjustments to the loss from operations as disclosed in the Group
Statement of Comprehensive Income relate to depreciation and
amortisation, share based payment charges, exceptional items and
losses related to the fair value of the Lanstead sharing
agreements.
|
12
months ended 30 September 2023
|
18
months ended 30 September 2022
|
|
Continuing Operations
£'000
|
Discontinued Operations
£'000
|
Total
£'000
|
Continuing Operations
£'000
|
Discontinued Operations
£'000
|
Total
£'000
|
|
|
|
|
|
|
|
(Loss)/profit from operations
|
(13,716)
|
-
|
(13,716)
|
(7,693)
|
(130)
|
(7,823)
|
Depreciation and amortisation
|
1,410
|
-
|
1,410
|
2,126
|
41
|
2,167
|
Share
based payments
|
530
|
-
|
530
|
1,510
|
-
|
1,510
|
Exceptional items
|
8,765
|
-
|
8,765
|
463
|
64
|
527
|
Other
losses
|
-
|
-
|
-
|
1,191
|
-
|
1,191
|
Adjusted
LBITDA
|
(3,011)
|
-
|
(3,011)
|
(2,403)
|
(25)
|
(2,428)
|
Exceptional items of £8.77 million
in the year (£2022: £0.46 million) relate to an impairment review
of goodwill, capitalised development costs and tangible assets as a
result of the delay in market traction, the Company's market
capitalisation and also to align with the turnaround
strategy.
The reported loss before tax for
continuing operations was £14.27 million (2022: £8.32 million).
Group net assets at 30 September 2023 were £1.08 million (30
September 2022: £11.6 million) with cash at the period end of £0.6
million (30 September 2022: £1.4 million).
Net cash used in operating
activities was £2.74 million (2022: £3.68 million) with trade and
other payables reducing by £0.82 million (2022: £1.98 million).
Investment in development costs and equipment was £0.34 million
(2022: £4.66 million) and net principal lease payments were £0.81
million (2022: £0.93 million) giving total cash outflows of £3.89
million (2022: £9.27 million).
These activities were financed by
net funds received from the Lanstead sharing agreements £nil (2022:
£3.53 million), the issue of shares £3.13 million (£1.92 million)
less net loans repaid of £0.1m, (2022: £2.78 million net loans
received) totaling £3.03m.
The deficit of £ 0.86 million
(2022: £1.04 million) resulted in a modest increase on drawings on
the invoice finance facilities of £0.10 million (2022: £0.03
million increase) thus reducing cash at the period-end by £0.76
million (2022: £1.01 million decrease).
Repayment of our GSCALE loan of £5
million is due to commence in 2025.
Technology Businesses
The technology businesses have
seen an decrease in revenue from £2.15
million to £0.24 million driven mainly by the recognised revenues
from the DSTL contract in the prior period. Operating costs for the
12 months, excluding exceptional items, were £2.83 million compared
to £4.50 million for the prior 18 month period. All development
costs not related to construction, textiles and polygrene
thermoplastics have been fully impaired along with £0.86 million of
production plant to align with our light manufacturing
strategy.
Mature Businesses
The mature business segment has seen decreased revenues of 13% on a pro rata basis, and returned a loss from operations of £0.18 million for 12 months
compared to the previous 18 months
profit of £0.03 million. As referred to in
the Chief Executive Officer's report, we continue to market these
for sale.
Going Concern
The financial statements have been
prepared on a going concern basis and are subject to the matters
described in note 1.
Chris Leigh
Chief Financial Officer
Group statement of comprehensive income
For the year ended 30 September
2023
|
Note
|
|
12 months
to
30
September
2023
£'000
|
18
months to
30
September
2022
£'000
|
Continuing operations
Revenue
Cost of sales
|
|
2
|
|
5,448
(4,286)
|
11,106
(7,739)
|
Gross profit
Other operating income
Other losses *
Operating expenses (including
exceptional items)
|
|
|
1,162
138
-
(15,016)
|
3,367
257
(1,191)
(10,126)
|
Loss from operations before
exceptional items
Exceptional items
|
|
3
|
|
(4,951)
(8,765)
|
(7,230)
(463)
|
Loss from operations
Finance costs
Finance income
|
|
|
13,716
(565)
16
|
(7,693)
(644)
14
|
Loss before income tax
Income tax
|
4
|
|
(14,265)
86
|
(8,323)
59
|
Loss from continuing operations
|
|
|
(14,179)
|
(8,264)
|
(Loss)/Profit from discontinued
operations
|
|
|
|
-
|
(141)
|
Loss for the period
|
|
|
(14,179)
|
(8,405)
|
Loss attributable to:
Owners of the parent
company
Non-controlling
interest
|
|
|
(13,525)
(654)
|
(8,069)
(336)
|
|
|
|
(14,179)
|
(8,405)
|
Loss per share attributable to the equity holders of the
Company:
Basic and diluted loss per
share
|
5
|
|
(5.49)p
|
(4.16)p
|
There is no other comprehensive income for the
period
|
|
|
|
|
|
|
|
|
|
| |
* The other losses in the
comparative period relate to the fair value assessment of the
Lanstead sharing agreements.
Group statement of financial position
As at 30 September 2023
|
|
30
September
|
30
September
|
|
|
2023
|
2022
|
|
Note
|
£'000
|
£'000
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Intangible assets
|
6
|
2,763
|
10,636
|
Property, plant and
equipment
|
7
|
3,443
|
5,861
|
Deferred taxation
|
|
-
|
25
|
Trade and other
receivables
|
|
36
|
38
|
|
|
6,242
|
16,560
|
Current assets
|
|
|
|
Inventory
|
|
1,528
|
2,131
|
Trade and other
receivables
|
|
1,409
|
2,155
|
Assets held for sale
|
|
604
|
-
|
Cash and cash
equivalents
|
|
596
|
1,351
|
|
|
4,137
|
5,637
|
Total assets
|
|
10,379
|
22,197
|
|
|
|
|
Equity
|
|
|
|
Called up share capital
|
8
|
3,308
|
1,941
|
Share premium account
|
8
|
36,724
|
34,961
|
Merger reserve
|
|
1,256
|
1,256
|
Share-based payment
reserve
|
|
5,289
|
4,759
|
Accumulated losses
|
|
(43,382)
|
(29,694)
|
Equity attributable to owners of
the parent company
|
|
3,195
|
13,223
|
Non-controlling
interest
|
|
(2,115)
|
(1,624)
|
Total equity
|
|
1,080
|
11,599
|
|
|
|
|
Liabilities
|
|
|
|
Non-current liabilities
|
|
|
|
Trade and other
payables
|
|
501
|
600
|
Deferred tax
liabilities
|
|
6
|
67
|
Innovate Loan
|
|
5,000
|
5,000
|
Long-term borrowings
|
|
995
|
1,595
|
|
|
6,502
|
7,262
|
Current liabilities
|
|
|
|
Trade and other
payables
|
|
1,479
|
1,957
|
Invoice discounting
advances
|
|
762
|
660
|
Current portion of long-term
borrowings
|
|
556
|
719
|
|
|
2,797
|
3,336
|
Total liabilities
|
|
9,299
|
10,598
|
Total equity and liabilities
|
|
10,379
|
22,197
|
Group statement of changes in equity
For year ended 30 September
2023
|
Share
capital
|
Share
premium account
|
Merger
reserve
|
Share-based payment reserve
|
Accumulated losses
|
Non-controlling interest
|
Total
equity
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
At 31 March 2021
|
1,899
|
33,003
|
1,256
|
3,249
|
(21,625)
|
(1,228)
|
16,494
|
Issue of shares
|
42
|
1,958
|
-
|
-
|
-
|
-
|
2,000
|
Loss for the period
|
-
|
-
|
-
|
-
|
(8,069)
|
(336)
|
(8,405)
|
Share-based payments
|
-
|
-
|
-
|
1,510
|
-
|
-
|
1,510
|
At 30 September 2022
|
1,941
|
34,961
|
1,256
|
4,759
|
(29,694)
|
(1,624)
|
11,599
|
Re-allocation of minority
interest
|
-
|
-
|
-
|
-
|
(163)
|
163
|
-
|
Issue of shares
|
1,367
|
1,763
|
-
|
-
|
-
|
-
|
3,130
|
Loss for the period
|
-
|
-
|
-
|
-
|
(13,525)
|
(654)
|
(14,179)
|
Share-based payments
|
-
|
-
|
-
|
530
|
-
|
-
|
530
|
At 30 September 2023
|
3,308
|
36,724
|
1,256
|
5,289
|
(43,382)
|
(2,115)
|
1,080
|
Statement of Group cash flows
For the year ended 30 September
2023
|
|
12 months
to
30
September
2023
£'000
|
18
months to
30
September
2022
£'000
|
Cash
flows from operating activities
|
|
|
|
Cash used in operations
|
|
(2,377)
|
(3,280)
|
Interest paid
|
|
(364)
|
(402)
|
Net
cash used in operating activities
|
|
(2,741)
|
(3,682)
|
Cash
flows from investing activities
|
|
|
|
Purchase of intangible
assets
|
|
(149)
|
(2,751)
|
Purchase of property, plant and
equipment
|
|
(187)
|
(1,910)
|
Net
cash used in investing activities
|
|
(336)
|
(4,661)
|
Cash
flows from financing activities
|
|
|
|
Share issue (net of funds deferred
per sharing agreement)
|
|
3,351
|
1,926
|
Share issue costs
|
|
(221)
|
(10)
|
Funds received from Innovate
UK
|
|
-
|
2,740
|
Funds received from sharing
agreements
|
|
-
|
3,537
|
Paymentof CBILS
|
|
(99)
|
41
|
Principal payment of leases under
IFRS 16
|
|
(811)
|
(928)
|
Invoice discounting loan
(repayments)/proceeds
|
|
102
|
29
|
Net
cash generated from financing activities
|
|
2,322
|
7,335
|
(Decrease)/increase in cash and cash
equivalents
|
|
(755)
|
(1,008)
|
Cash and cash equivalents at
beginning of period
|
|
1,351
|
2,359
|
Cash
and cash equivalents at end of period
|
|
596
|
1,351
|
Note to the statement of Group cash flows
For the year ended 30 September
2023
|
12 months
to
30
September
2023
£'000
|
18 months
to
30
September
2022
£'000
|
Loss before tax (including
discontinued operations)
|
(14,265)
|
(8,464)
|
Adjustments for:
|
|
|
Share-based payments
|
530
|
1,510
|
Depreciation
|
1,108
|
1,677
|
Amortisation
|
302
|
490
|
Disposal of tangible
assets
|
181
|
292
|
Impairment of tangible
assets
|
861
|
-
|
Impairment of intangible
assets
|
7,720
|
1,331
|
Finance cost/(income)
|
549
|
630
|
Loss/(gain) on FV movement of
sharing agreement
|
-
|
1,191
|
R&D tax credit
repayment
|
86
|
59
|
*Decrease/(increase) in trade and
other receivables and investments
|
771
|
301
|
(Increase)/decrease in
inventories
|
603
|
(317)
|
(Decrease)/increase in trade and
other payables
|
(823)
|
(1,980)
|
Cash flows from operating
activities
|
(2,377)
|
(3,280)
|
Notes to the final results
For the 12 months ended 30
September 2023
1. Basis of preparation
The Group consolidated financial
statements have been prepared in accordance with UK-adopted,
International Accounting Standards in conformity with the
requirements of the Companies Act 2006.
The Group's financial statements
have been prepared on a going concern basis under the historical
cost convention
However, whilst the Company
continues to develop and seek to commercialise its graphene
technology it remains reliant upon the capital markets and/or asset
sales to continue as a going concern up until such time as it
generates sufficient revenues to cover its costs. It has therefore
taken the following steps in the last twelve months:
· It has
reduced its cost base by closing down operations in the US and
China.
· It has
reduced its employee base from 93 employees to 64
employees.
· It is
seeking to sell its mature businesses which employ 42 staff which
would leave 22 staff in its core technology business.
The Directors have prepared
detailed projections of expected future cash flows for a period of
twelve months from the date of issue of these results and have made
the following assumptions in support of adopting the going concern
basis in preparation of these financial statements:
· Versarien's shareholders will continue to give authority to
the Directors to issue sufficient shares without pre-emption rights
to enable the Company to raise cash on the capital markets. With
the Company's low market capitalisation this is likely to require a
staged approach until such time as the value of the Company
increases. Consequently, there is no certainty as to timing or
quantum, but the Company has a history of raising capital on a
regular basis. The Company is expected to meet the criteria for
EIS/VCT investment which potentially widens the capital pool it may
access.
· The
Company will be able to sell its mature businesses having already
sold its Korean plant with receipts due on a staged
basis.
Following the recent issue of 492
million shares at 0.125p per share, the Company has a bank balance
of £0.8 million and headroom on its invoice discounting facilities
of £0.1 million totalling £0.9 million. This together with the
expected receipts of £0.5 million from the sale of the South Korean
plant and equipment are expected to provide working capital until
the fourth quarter of the calendar year. In making their going concern assessment, and the Directors have
forecast that sufficient additional funding will be raised to
enable the group and parent company to meet liabilities as they
fall due for a period of at least 12 months from the date of
approval of the financial statements.
The notice of Annual General
Meeting contains resolutions which are anticipated to be sufficient
for further working capital needs and which will be used if the
Company is unable to realise cash from the sale of its mature
businesses.
After due consideration, the
Directors have concluded that it is appropriate to prepare the
financial statements on a going concern basis subject to raising
the required funds either through asset sales and/or raising
sufficient equity.
However, as there is no certainty
as to the completion of the matters noted above, this represents a
material uncertainty that may cast significant doubt on the Group
and Parent Company's ability to continue as a going concern and
therefore it may be unable to realise its assets and discharge its
liabilities in the normal course of business. The financial
statements do not include the adjustments that would result if the
Group was unable to continue as a going concern.
The auditors' report on the Annual
Report and Financial Statements for the period ended 30 September
2023 was unqualified, did not contain a statement under s498(2) or
s498(3) of the Companies Act 2006 but drew attention to material
uncertainty with regard to going concern as follows:
We draw attention to the going
concern section of the accounting policies of the financial
statements which indicates that the group remains reliant upon the
capital markets and/or asset sales to continue as a going concern
up until such time as it generates sufficient revenues to cover its
costs, and that additional funding will need to be raised within 12
months from the date of approval of the financial statements. The
group and parent company expect to be able to secure this
additional funding to enable the group and parent company to
realise their assets and discharge their liabilities in the normal
course of business.
As stated in the going concern
section of the accounting policies, these events and conditions,
along with other matters set out in the going concern section of
the accounting policies, indicate that a material uncertainty
exists that may cast significant doubt on the Group and Parent
Company's ability to continue as a going concern. Our opinion is
not modified in respect of this matter.
Given the material uncertainty
noted above and our risk assessment, we considered going concern to
be a key audit matter. Our evaluation of the Directors' assessment
of the Group and the Parent Company's ability to continue to adopt
the going concern basis of accounting and in response to the key
audit matter included:
· Obtaining an understanding of how the Directors undertook the
going concern assessment process to determine if we considered it
to be appropriate in the circumstances;
· Challenge of the Directors' going concern assessment,
including the reasonableness of assumptions and downside stress
case sensitivities applied, using our underlying knowledge of the
business;
· Testing of the mathematical accuracy, and consideration of
the reasonableness, of the assumptions made and available headroom
throughout the forecast period extending from the date of approval
of the financial statements;
· Consideration of the key sensitivities applied in the cash
flow model pertaining to revenue, grant income and cost base, the
continued use of the finance facilities and management of the
Group's and Company's cost base;
· Analysing post year end trading results compared to forecast
and current year to evaluate the accuracy and achievability of
forecasts; and
· Assessing the completeness and accuracy of disclosures in
relation to going concern and whether significant judgements have
been appropriately disclosed.
In auditing the financial
statements, we have concluded that the Directors' use of the going
concern basis of accounting in the preparation of the financial
statements is appropriate.
The consolidated financial
statements are presented in sterling amounts. Amounts are rounded
to the nearest thousands, unless otherwise stated.
The financial information
contained in this announcement does not constitute the Group's
statutory accounts for the period ended 30 September 2023 but is
derived from those accounts which have been audited and which will
be filed with the Registrar of Companies in due course.
2. Segmental information
At 30 September 2023, the Group is
organised into two business segments. Central costs are reported
separately. Information reported to the Group's Chief Executive
Officer for the purposes of resource allocation and assessment of
segment performance is focussed on the two principal business
segments of Technology and Mature Businesses, and, accordingly, the
Group's reportable segments under IFRS 8 are based on these
activities.
Segment profit/(loss) represents
the profit/(loss) earned by each segment, including a share of
central administration costs, which are allocated on the basis of
time spent by central staff on subsidiary affairs. This is the
measure reported to the Chief Executive Officer for the purposes of
resource allocation and assessment of segment
performance.
The non-core aluminium operations
of Versarien Technologies Limited were closed in the prior period
and are presented below as discontinued operations.
|
Central
|
Technology
Businesses
|
Mature
Businesses
|
Intra-group
adjustments
|
Total continuing
Operations
|
Discontinued
Operations
|
Total
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Revenue
|
-
|
239
|
5,209
|
-
|
5,448
|
-
|
5,448
|
Gross profit
|
-
|
(560)
|
1,722
|
-
|
1,162
|
-
|
1,162
|
Other operating income
|
-
|
133
|
5
|
-
|
138
|
-
|
138
|
Other losses
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating expenses
|
(15,141)
|
(5,136)
|
(1,903)
|
7,164
|
(15,016)
|
-
|
(15,016)
|
(Loss)/Profit from
operations
|
(15,141)
|
(5,563)
|
(176)
|
7,164
|
(13,716)
|
-
|
(13,716)
|
Finance charge
|
256
|
(690)
|
(115)
|
-
|
(549)
|
-
|
(549)
|
Loss
before tax
|
(14,885)
|
(6,253)
|
(291)
|
7,164
|
(14,265)
|
-
|
(14,265)
|
Total assets
|
6,207
|
5,766
|
5,392
|
(6,986)
|
10,379
|
-
|
10,379
|
Total liabilities
|
(6,557)
|
(25,617)
|
(2,554)
|
25,429
|
(9,299)
|
-
|
(9,299)
|
Net
assets/(liabilities)
|
(350)
|
(19,851)
|
2,838
|
18,443
|
1,080
|
-
|
1,080
|
Capital expenditure
|
87
|
391
|
9
|
-
|
487
|
-
|
487
|
Depreciation/amortisation and
impairment
|
6,448
|
3,053
|
489
|
-
|
9,990
|
-
|
9,990
|
The segment analysis for the 18
months ended 30 September 2022 is as follows:
|
|
|
Technology
|
Mature
|
Intra-group
|
Total
|
|
|
|
Central
|
Businesses
|
Businesses
|
adjustments
|
Continuing operations
|
Discontinued Operations
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Revenue
|
-
|
2,146
|
8,960
|
-
|
11,106
|
534
|
11,640
|
Gross profit
|
(29)
|
1,008
|
2,388
|
-
|
3,367
|
107
|
3,474
|
Other operating income
|
-
|
251
|
6
|
-
|
257
|
1
|
258
|
Other losses
|
(1,191)
|
-
|
-
|
-
|
(1,191)
|
-
|
(1,191)
|
Operating expenses
|
(14,916)
|
(4,740)
|
(2,365)
|
11,895
|
(10,126)
|
(238)
|
(10,364)
|
(Loss)/Profit from
operations
|
(16,136)
|
(3,481)
|
29
|
11,895
|
(7,693)
|
(130)
|
(7,823)
|
Finance charge
|
159
|
(76)
|
(104)
|
(609)
|
(630)
|
(11)
|
(641)
|
Loss
before tax
|
(15,977)
|
(3,557)
|
(75)
|
11,286
|
(8,323)
|
(141)
|
(8,464)
|
Total assets
|
15,824
|
9,232
|
7,319
|
(10,178)
|
22,197
|
-
|
22,197
|
Total liabilities
|
(5,853)
|
(22,292)
|
(2,997)
|
20,544
|
(10,598)
|
-
|
(10,598)
|
Net
assets/(liabilities)
|
9,971
|
(13,060)
|
4,322
|
10,366
|
11,599
|
-
|
11,599
|
Capital expenditure
|
403
|
5,005
|
1,054
|
-
|
6,462
|
-
|
6,462
|
Depreciation/amortisation and
impairment
|
566
|
1,480
|
993
|
459
|
3,498
|
-
|
3,498
|
3.
Exceptional items
|
12 months
to
30
September
2023
£'000
|
18
months to
30
September
2022
£'000
|
Continuing Operations
|
|
|
Goodwill impairment
|
3,132
|
423
|
Development cost
impairment
Patent and trademarks
impairment
|
1,864
2,724
|
908
-
|
Tangible asset impairment
|
861
|
-
|
Deferred income related to
development cost impairment
|
(238)
|
(660)
|
Restructuring costs
|
483
|
-
|
(Credit)/charge relating to expansion
in Asia
|
-
|
(306)
|
Acquisition costs
|
-
|
82
|
Other
|
(61)
|
16
|
|
8,765
|
463
|
Discontinued Operations
|
|
|
Relocation and restructuring
costs
|
-
|
64
|
4.
Taxation
The tax credit for the period of
£86,000 (2022: £59,000) relates to an R&D tax credit. The
charge on the results for the period is £nil (2022: £nil). At the
year end the Group had £33.3 million (2022: £25.5 million) of
trading losses carried forward to set-off against future trading
profits.
5. Loss per share
The calculation of the basic loss
per share for the year ended 30 September 2023 and period ended 30
September 2022 is based on the losses attributable to the
shareholders of Versarien plc divided by the weighted average
number of shares in issue during the period. The calculation of
diluted loss per share is based on the basic loss per share
adjusted to allow for the issue of shares on the assumed conversion
of all dilutive options. However, in accordance with IAS 33
"Earnings per Share", potential Ordinary shares are only considered
dilutive when their conversion would decrease the profit per share
or increase the loss per share.
As at 30 September 2023, there
were 12,914,730 (2022: 15,205,850) potential Ordinary shares, which
have been disregarded in the calculation of diluted loss per share
as they were considered non-dilutive at that date.
|
Attributable to owners of parent company
|
Weighted
average number of shares
|
Basic
loss per share pence
|
|
£'000
|
'000
|
|
12
months ended 30 September 2023
|
(13,525)
|
246,401
|
(5.49)
|
18 months ended 30 September
2022
|
(8,069)
|
194,027
|
(4.16)
|
6. Intangible assets
|
|
Development
|
Patents,
trademarks and other
|
|
|
Goodwill
£'000
|
Costs
£'000
|
Intangibles
£'000
|
Total
£'000
|
Cost
|
|
|
|
|
At 1 April 2021
|
4,431
|
2,965
|
4,500
|
11,896
|
Additions
|
-
|
2,584
|
167
|
2,751
|
At 30 September 2022
|
4,431
|
5,549
|
4,667
|
14,647
|
Additions
|
-
|
-
|
149
|
149
|
At
30 September 2023
|
4,431
|
5,549
|
4,816
|
14,796
|
Accumulated amortisation and impairment
|
|
|
|
|
At 1 April 2021
|
876
|
491
|
823
|
2,190
|
Amortisation charge
|
-
|
1
|
489
|
490
|
Impairment
|
423
|
908
|
-
|
1,331
|
At 30 September 2022
|
1,299
|
1,400
|
1,312
|
4,011
|
Amortisation charge
|
-
|
1
|
301
|
302
|
Impairment
|
3,132
|
1,864
|
2,724
|
7,220
|
At
30 September 2023
|
4,431
|
3,265
|
4,337
|
12,033
|
Carrying value
|
|
|
|
|
At
30 September 2023
|
-
|
2,284
|
479
|
2,763
|
At 30 September 2022
|
3,132
|
4,149
|
3,355
|
10,636
|
7. Property, plant and equipment
|
|
ROU
asset
|
Plant
and equipment
|
Leasehold improvements
|
Total
|
|
|
£'000
|
£'000
|
£'000
|
£'000
|
Cost
|
|
|
|
|
|
At 1 April 2021
|
|
6,537
|
6,288
|
518
|
13,343
|
Additions
|
|
1,801
|
1,776
|
134
|
3,711
|
Disposals
|
|
(1,742)
|
(30)
|
(84)
|
(1,856)
|
At 30 September 2022
|
|
6,596
|
8,034
|
568
|
15,198
|
Additions
|
|
149
|
184
|
4
|
337
|
Disposals
|
|
(883)
|
(192)
|
(35)
|
(1,110)
|
Transfer of assets held for
sale
|
|
-
|
(1,083)
|
-
|
(1,083)
|
At
30 September 2023
|
|
5,862
|
6,943
|
537
|
13,342
|
Accumulated depreciation
|
|
|
|
|
|
At 1 April 2021
|
|
4,199
|
4,890
|
135
|
9,224
|
Charge for the year
|
|
1,113
|
455
|
109
|
1,677
|
Disposals
|
|
(1,505)
|
(27)
|
(32)
|
(1,564)
|
At 30 September 2022
|
|
3,807
|
5,318
|
212
|
9,337
|
Charge for the period
|
|
642
|
392
|
74
|
1,108
|
Disposals
|
|
(702)
|
(191)
|
(35)
|
(928)
|
Transfer of assets held for
sale
|
|
-
|
(479)
|
-
|
(479)
|
Impairment
|
|
-
|
861
|
-
|
861
|
At
30 September 2023
|
|
3,747
|
5,901
|
251
|
9,889
|
Net
book value
|
|
|
|
|
|
At
30 September 2023
|
|
2,115
|
1,042
|
286
|
3,443
|
At 31 March 2022
|
|
2,789
|
2,716
|
356
|
5,861
|
8. Called up share capital and share
premium
|
Number
of shares
|
Called
up share capital
|
Share
premium
|
Total
|
'000
|
£'000
|
£'000
|
£'000
|
At 1 April 2021
|
189,8710
|
1,899
|
33,003
|
34,902
|
Issue of shares
|
4,280
|
42
|
1,958
|
2,000
|
At 30 September 2022
|
194,150
|
1,941
|
34,961
|
36,902
|
Issue of shares
|
136,629
|
1,367
|
1,763
|
3,129
|
At
30 September 2023
|
330,779
|
3,308
|
36,724
|
40,031
|
The called up share capital in the
table above represents the total number of authorised, issued and
fully paid Ordinary shares with a nominal value of 0.01p per
share.